Strata Critical Medical, Inc. Announces Strong Financial Performance in 2025
Strata Critical Medical, Inc., formerly known as Blade Air Mobility Inc., has released its annual report for 2025, showcasing a remarkable turnaround and growth in its financial performance. The company operates as a logistics and medical services provider within the U.S. healthcare sector, focusing primarily on organ transport and surgical services.
1. Overview of the Business
Strata has established a robust network dedicated to air transport and surgical services for transplant hospitals and organ procurement organizations. With its mission to increase the number of successful organ transplants, the company has expanded its offerings in logistics and clinical services. As of the fourth quarter of 2025, Strata operates through two segments: Logistics, branded as Trinity, and Clinical, branded as Keystone.
2. Financial Highlights
The financial results for the year ended December 31, 2025, indicate a strong performance:
- Total Revenue: Strata reported a total revenue of $197.1 million, marking a significant increase of 34.3% compared to $146.8 million in 2024. This growth can be attributed to a 20.4% increase in Logistics revenue and the introduction of Clinical revenue following the acquisition of Keystone Perfusion Services, LLC.
- Gross Profit: The gross profit for the Logistics segment rose by $7.1 million, with gross margins improving from 20% to 21%.
- Net Income: Strata reported a net income of $41.34 million, reflecting a positive shift from a net loss of $27.30 million in 2024.
Revenue by Segments
The breakdown of revenue by segments for 2025 is as follows:
Revenue by Geography
Strata's revenue by geography highlights its strong domestic presence:
Revenue by Products or Services
The revenue generated from various products and services is detailed below:
3. Recent Transactions and Strategic Initiatives
Divestiture of Passenger Business
In a strategic move, Strata completed the sale of its Passenger business to Joby Aero, Inc. for approximately $76.0 million on August 29, 2025. This divestiture has allowed the company to focus more on its core logistics and clinical services, with the results from the Passenger business classified as discontinued operations.
Acquisition of Keystone Perfusion Services
On September 16, 2025, Strata acquired Keystone Perfusion Services, LLC for $111.3 million. This acquisition is expected to significantly enhance Strata’s clinical service offerings, contributing to future revenue growth and operational efficiencies.
4. Financial Condition
As of December 31, 2025, Strata reported total assets of $325.4 million, a substantial increase from $256.6 million in 2024. The company’s liquidity position remains strong, with cash and short-term investments amounting to $61.2 million. Strata also established a revolving credit facility of $30.0 million, enhancing its financial flexibility.
Balance Sheet Overview
The company’s balance sheet reflects its robust financial position:
| Mar 2025 | Mar 2026 | |
|---|---|---|
Total Assets | 256.6M | 325.4M |
Total Current Assets | 160.7M | 126.1M |
Cash and Equivalents | 18.37M | 30.96M |
Short-term Investments | 108.7M | 30.26M |
Accounts Receivable | 21.59M | 39.95M |
Restricted Cash and Investments | 1.26M | 264K |
Prepaid Expenses | 10.74M | 24.73M |
Total Non-current Assets | 95.93M | 199.2M |
Intangible Assets | 54.70M | 135.7M |
Net PP&E | 30.91M | 36.44M |
Lease Assets | 8.87M | 3.10M |
Other Non-current Assets | 1.43M | 24.01M |
Total Liabilities and Equity | 256.6M | 325.4M |
Total Liabilities | 34.73M | 46.4M |
Total Current Liabilities | 22.72M | 19.79M |
Accounts Payable and Accrued Liabilities | 12.76M | 19.14M |
Current Debt | 3.30M | 652K |
Current Deferred Revenue | 6.65M | 0 |
Total Non-current Liabilities | 12.01M | 26.60M |
Non-current Deferred Tax Liabilities | 185K | 348K |
Other Non-current Liabilities | 11.82M | 26.25M |
Total Equity and Non-controlling Interests | 221.9M | 279.0M |
Total Equity | 221.9M | 279.0M |
Income Statement Analysis
The income statement for 2025 indicates a healthy growth trajectory for Strata:
| Mar 2025 | Mar 2026 | |
|---|---|---|
Net Income | -27.30M | 41.34M |
Profit | -27.30M | 41.34M |
Net Income Discontinued | 0 | 61.41M |
Net Income Continuing | -27.30M | -20.06M |
Income Tax Expense | -255K | 0 |
Pretax Income | -27.56M | -20.06M |
Non-operating Income | 6.36M | 2.28M |
Operating Income | -33.92M | -22.35M |
Revenue | 248.6M | 197.1M |
Costs and Expenses | 282.6M | 219.4M |
Cost of Revenue | 189.7M | 156.0M |
Operating Expenses | 92.84M | 63.47M |
Depreciation, Depletion & Amortization | 0 | 2.60M |
Research & Development | 3.18M | 0 |
Selling, General & Administrative | 89.66M | 60.87M |
Cash Flow Statement Insights
The cash flow statement highlights the company’s operational dynamics and investment activities:
| Mar 2025 | Mar 2026 | |
|---|---|---|
Net Change in Cash | -9.37M | 11.58M |
Effect of Exchange Rate Changes | -80K | -339K |
Net Cash from Operating Activities | -2.51M | -48.91M |
Operating Profit | -27.30M | 41.34M |
Adjustment to Operating Profit | 24.78M | -90.26M |
Net Cash from Investing Activities | -1.01M | 69.75M |
Business & Interest in Affiliates | 2.23M | 66.53M |
Investments | -34.19M | -150.1M |
Productive Assets | 32.98M | 11.01M |
Other Investing Activities | 0 | -2.81M |
Net Cash from Financing Activities | -5.75M | -8.91M |
Equity Issuance/Repurchase | -76K | 8.60M |
Other Financing Activities | -5.68M | -17.51M |
5. Challenges and Outlook
Despite its strong performance, Strata faces ongoing challenges related to the availability of donor organs, which could affect operational efficiency. Additionally, competitive pressures in both logistics and clinical service markets require continuous innovation and adaptation. The company is actively pursuing long-term capacity purchase agreements to mitigate risks associated with aircraft availability.
6. Conclusion
Strata Critical Medical, Inc. is well-positioned for future growth, driven by strategic acquisitions and a focus on enhancing its service offerings. With a strong financial performance in 2025, the company is set to navigate industry challenges while maintaining a competitive edge in healthcare logistics and clinical services. The successful execution of its strategic initiatives underscores Strata's commitment to improving organ transplant outcomes and expanding its market presence.
